AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$GLUE

Bowen Matthew sold $137 of GLUE

Bowen Matthew (Principal Accounting Officer) sold 13 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $10.56 on 2026-10-05.

Original reporting
SEC EDGAR · Bowen Matthew
Published Oct 6, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GLUE
Bearish
high confidence
Mentioned
$GLUE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUEBearishLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock significantly.

02

Market read

A minor insider transaction with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing unrelated to company outlook.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Monte Rosa Therapeutics filed a Form 4 reporting an insider sale.

Company-level read

Ticker impact

$GLUEBearishHigh confidence
Context

Form 4 disclosed a 13‑share sale by Principal Accounting Officer Bowen Matthew for $137.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

The sale is small ($137) but represents a direct insider disposition, which can prompt short‑term selling pressure.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale may be routine and not indicative of future performance.

Key entities

  • Company
    Monte Rosa Therapeutics, Inc.

    Biotech firm listed on NASDAQ under GLUE.

  • Person
    Bowen Matthew

    Principal Accounting Officer of Monte Rosa Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GLUE insider trading history →

Related articles

OCT 11
$GLUEMed

Monte Rosa Therapeutics assumed with a Buy at UBS

UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.

tipranks.com1 min
OCT 5
$GLUEMedAI 8/10

H.C. Wainwright reiterates Monte Rosa stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.

investing.com2 min
OCT 3
$GLUEMedAI 8/10

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Monte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing significant biomarker reductions and no serious adverse events. The data supports its planned Phase 2b study in coronary artery disease. The company forecasts revenue of $88.1M and earnings of $15.2M by 2029, with current losses of $161.1M and revenue of $28.7M.

simplywall.st2 min
OCT 1
$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.

rttnews.com2 min